IDiyas

For the Inventor, By the Inventor

Carlsbad, CA, United States of America

John A Drewe

USPTO Granted Patents = 30 


Average Co-Inventor Count = 4.7

ph-index = 11

Forward Citations = 444(Granted Patents)


Location History:

  • Costa Mesa, CA (US) (2000 - 2007)
  • Carlsbad, CA (US) (2004 - 2011)

Company Filing History:

goldMedal30 out of 47 
 
Cytovia, Inc.
 patents
silverMedal1 out of 4 
 
Myriad Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 16 
 
Shire Biochem, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2000-2011

Loading Chart...
Loading Chart...
30 patents (USPTO):
1. 7968595 - Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof (2011-06-28),
2. 7732468 - [object Object] (2010-06-08),
3. 7618975 - 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2009-11-17),
4. 7507762 - [object Object] (2009-03-24),
5. 7435750 - Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof (2008-10-14),
6. 7270801 - Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof (2007-09-18),
7. 7256219 - Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof (2007-08-14),
8. 7235674 - Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2007-06-26),
9. 7226927 - Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2007-06-05),
10. 7176234 - Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis (2007-02-13),
11. 7135480 - Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis (2006-11-14),
12. 7074813 - Substituted N'-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof (2006-07-11),
13. 7041685 - Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof (2006-05-09),
14. 7015328 - Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2006-03-21),
15. 6984718 - Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof (2006-01-10),

Title: John A. Drewe: Innovator in Apoptosis Induction and Oncology Therapeutics

Introduction

John A. Drewe, based in Carlsbad, CA, is a prolific inventor with a remarkable portfolio of 30 patents. His innovative works primarily focus on the activation of caspases and the induction of apoptosis, both critical processes in combating various clinical conditions characterized by the uncontrolled growth of abnormal cells.

Latest Patents

Among his latest inventions, Drewe has developed substituted 4-aryl-chromene compounds that serve as activators of caspases and inducers of apoptosis. This compound, represented by a specific formula, is noteworthy for being substantially free from its corresponding (S)-stereoisomer. Its therapeutic applications include inducing cell death in conditions such as solid tumors and ocular neovascularization, thereby targeting diseases caused by excessive vasculature growth. Additionally, he has disclosed 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds, which similarly act as activators of caspases and represent a significant advancement in cancer treatment methodologies.

Career Highlights

Drewe has had a distinguished career, contributing his expertise to notable companies such as Cytovia, Inc. and Myriad Pharmaceuticals, Inc. His work in these organizations has been instrumental in advancing research and development in therapeutic interventions for oncology.

Collaborations

Throughout his innovative journey, Drewe has collaborated with esteemed professionals including Sui Xiong Cai and Han-Zhong Zhang. These partnerships have fostered an environment of creativity and knowledge sharing, ensuring that his inventions practically address pressing health issues.

Conclusion

John A. Drewe's contributions to the field of medicine through his inventive spirit and robust patent portfolio highlight the importance of innovation in developing treatments for cancer and other diseases. His ongoing work continues to pave the way for future advancements in medical science, demonstrating the profound impact that a dedicated inventor can have on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…